Ivosidenib combined with chemo and radiation for colorectal cancer
Treatments studied
Part of Cancer clinical trials.
This trial is testing a combination treatment for colorectal cancer that has spread to other parts of the body and cannot be removed with surgery. The treatment includes a drug called Ivosidenib, chemotherapy, and radiation therapy. It aims to see if this combination can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your cancer must be colorectal adenocarcinoma (a type of colorectal cancer) confirmed by biopsy.
- The cancer must have spread to other parts of your body and cannot be removed with surgery at the time of the study.
- You must have had either no prior treatment for your cancer, or completed initial treatment (like surgery and chemotherapy) more than a year ago.
- You must have good overall health (able to carry out daily activities, ECOG 0-1).
- You must have a specific type of colorectal cancer: one that is microsatellite stable (MSS) and has functional mismatch repair proteins.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (IBI351, cetuximab, and FOLFIRI) as first treatment or as a second treatment after standard chemotherapy for people with KRAS G12C mutated colorectal cancer that has spread. The goal is to see if it works well and is safe.
This trial tests a combination of three drugs (irinotecan liposomes, cetuximab, and vemurafenib) for people with advanced colorectal cancer that has a specific genetic change (BRAF V600E mutation) and did not respond to first treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a new combination of drugs (liposomal irinotecan, 5-FU/LV, and bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this treatment is safe and effective in shrinking tumors and improving outcomes.
This trial combines a special type of radiation, immunotherapy, a targeted blood-vessel drug, and a chemotherapy pill for patients whose colorectal cancer has continued to grow after two prior treatments. The hope is that this combination can shrink tumors or slow down the cancer better than current options.
This trial tests a new drug called ivonescimab combined with chemotherapy for people with metastatic colorectal cancer that has not spread to the liver. The goal is to see if this combination can help control the cancer better than chemotherapy alone.
This trial tests whether adding a new drug called ivonescimab to standard chemotherapy helps shrink advanced colon cancer before surgery. It may improve the chances of removing all the cancer and reduce the risk of it coming back.
Hear when a new CRC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.